Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
829
mi
from 91732
Portland, OR
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Oregon Center for Clinical Investigations, Inc.
829
mi
from 91732
Portland, OR
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
796
mi
from 91732
Salem, OR
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Oregon Center for Clinical Investigations, Inc
796
mi
from 91732
Salem, OR
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
2352
mi
from 91732
West Chester, PA
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Thomas Wind
2352
mi
from 91732
West Chester, PA
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
2560
mi
from 91732
Warwick, RI
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Richard Ohnmacht
2560
mi
from 91732
Warwick, RI
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
2096
mi
from 91732
Barnwell, SC
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Abraham Moskow
2096
mi
from 91732
Barnwell, SC
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
1224
mi
from 91732
Dallas, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Research Across America/Psychiatric Medical Associates
1224
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
1224
mi
from 91732
Dallas, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Michael Downing
1224
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
1351
mi
from 91732
Houston, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Clinical Trial Network
1351
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
1354
mi
from 91732
Houston, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Claghorn-Lesem Research Clinic
1354
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
1357
mi
from 91732
Houston, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Texas Center for Drug Development, P.A.
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
1357
mi
from 91732
Houston, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Houston Clinical Trials, LLC
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
1349
mi
from 91732
Houston, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Bayou City Research, Ltd.
1349
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
1357
mi
from 91732
Houston, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Red Oak Psychiatry Associates, PA
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
1370
mi
from 91732
Lake Jackson, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
R/D Clinical Research, Inc.
1370
mi
from 91732
Lake Jackson, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
926
mi
from 91732
Lubbock, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Westex Clinical Investigations
926
mi
from 91732
Lubbock, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
1188
mi
from 91732
San Antonio, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Tracy Schillerstrom
1188
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
1183
mi
from 91732
San Antonio, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
University of Texas Health Science Center at San Antonio
1183
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
1331
mi
from 91732
The Woodlands, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Marshall Lucas
1331
mi
from 91732
The Woodlands, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
586
mi
from 91732
Clinton, UT
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Ericksen Research and Development - Westside Medical
586
mi
from 91732
Clinton, UT
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
mi
from 91732
Charlottesville, VA
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
University of Virginia Child and Family Psychiatry Clinic
mi
from 91732
Charlottesville, VA
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
959
mi
from 91732
Bellevue, WA
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Northwest Clinical Research Center
959
mi
from 91732
Bellevue, WA
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
964
mi
from 91732
Kirkland, WA
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
James Knutson
964
mi
from 91732
Kirkland, WA
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
961
mi
from 91732
Seattle, WA
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Summit Research Network (Seattle) LLC
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
939
mi
from 91732
Spokane, WA
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Rockwood Clinic, PS
939
mi
from 91732
Spokane, WA
Click here to add this to my saved trials
Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months
A Prospective, Observational, Single-blinded, Longitudinal Optical Coherence Tomography Study of Effect of Copaxone (Glatiramer Acetate) on Retinal Nerve Fiber Layer Thickness in Patients With Relapsing-remitting Multiple Sclerosis Over 24 Months
Status: Enrolling
Updated:  2/11/2014
2180
mi
from 91732
Buffalo, NY
Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months
A Prospective, Observational, Single-blinded, Longitudinal Optical Coherence Tomography Study of Effect of Copaxone (Glatiramer Acetate) on Retinal Nerve Fiber Layer Thickness in Patients With Relapsing-remitting Multiple Sclerosis Over 24 Months
Status: Enrolling
Updated: 2/11/2014
Buffalo Neuroimaging Analysis Center
2180
mi
from 91732
Buffalo, NY
Click here to add this to my saved trials
The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy
The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy: A Pilot Study
Status: Enrolling
Updated:  2/12/2014
1524
mi
from 91732
Rochester, MN
The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy
The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy: A Pilot Study
Status: Enrolling
Updated: 2/12/2014
Mayo Clinic Rochester
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Status: Enrolling
Updated:  2/12/2014
353
mi
from 91732
Tempe, AZ
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
353
mi
from 91732
Tempe, AZ
Click here to add this to my saved trials
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Status: Enrolling
Updated:  2/12/2014
2318
mi
from 91732
South Miami, FL
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
2318
mi
from 91732
South Miami, FL
Click here to add this to my saved trials
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Status: Enrolling
Updated:  2/12/2014
1254
mi
from 91732
Lincoln, NE
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
1254
mi
from 91732
Lincoln, NE
Click here to add this to my saved trials
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Status: Enrolling
Updated:  2/12/2014
1188
mi
from 91732
San Antonio, TX
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
1188
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Ampyra for Optic Neuritis in MS
Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis
Status: Enrolling
Updated:  2/14/2014
1573
mi
from 91732
St. Louis, MO
Ampyra for Optic Neuritis in MS
Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis
Status: Enrolling
Updated: 2/14/2014
Washington University (John L. Trotter MS Center)
1573
mi
from 91732
St. Louis, MO
Click here to add this to my saved trials
Walnut Oral Immunotherapy for Tree Nut Allergy
Walnut Oral Immunotherapy for Tree Nut Allergy-CHOP
Status: Enrolling
Updated:  2/19/2014
2375
mi
from 91732
Philadelphia, PA
Walnut Oral Immunotherapy for Tree Nut Allergy
Walnut Oral Immunotherapy for Tree Nut Allergy-CHOP
Status: Enrolling
Updated: 2/19/2014
Children's Hospital of Philadelphia
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Acupuncture for Sexual Dysfunction
Acupuncture in Premenopausal Women With Hypoactive Sexual Desire Disorder: A Prospective Cohort
Status: Enrolling
Updated:  2/20/2014
1880
mi
from 91732
Cincinnati, OH
Acupuncture for Sexual Dysfunction
Acupuncture in Premenopausal Women With Hypoactive Sexual Desire Disorder: A Prospective Cohort
Status: Enrolling
Updated: 2/20/2014
TriHealth, Inc
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Vilazodone for Corticosteroid-Induced Memory Impairment
Vilazodone for Corticosteroid-Induced Memory Impairment
Status: Enrolling
Updated:  2/21/2014
1225
mi
from 91732
Dallas, TX
Vilazodone for Corticosteroid-Induced Memory Impairment
Vilazodone for Corticosteroid-Induced Memory Impairment
Status: Enrolling
Updated: 2/21/2014
U.T. Southwestern Medical Center
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Non-Invasive Brain Signal Training to Induce Motor Control Recovery After Stroke
Non-Invasive Brain Signal Training to Induce Motor Control Recovery After Stroke
Status: Enrolling
Updated:  2/23/2014
2102
mi
from 91732
Gainesville, FL
Non-Invasive Brain Signal Training to Induce Motor Control Recovery After Stroke
Non-Invasive Brain Signal Training to Induce Motor Control Recovery After Stroke
Status: Enrolling
Updated: 2/23/2014
Malcom Randall VA Medical Center
2102
mi
from 91732
Gainesville, FL
Click here to add this to my saved trials
Expiratory Muscle Conditioning in Multiple Sclerosis Using Magnetic Stimulation
Cleveland Clinic Research Program: Expiratory Muscle Conditioning Using Functional Magnetic Stimulation for Patients With Multiple Sclerosis
Status: Enrolling
Updated:  2/26/2014
2035
mi
from 91732
Cleveland, OH
Expiratory Muscle Conditioning in Multiple Sclerosis Using Magnetic Stimulation
Cleveland Clinic Research Program: Expiratory Muscle Conditioning Using Functional Magnetic Stimulation for Patients With Multiple Sclerosis
Status: Enrolling
Updated: 2/26/2014
Cleveland Clinic
2035
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
Status: Enrolling
Updated:  3/3/2014
2578
mi
from 91732
Boston, MA
An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
Status: Enrolling
Updated: 3/3/2014
Boston Children's Hospital
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
Status: Enrolling
Updated:  3/3/2014
2432
mi
from 91732
New York, NY
An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
Status: Enrolling
Updated: 3/3/2014
Columbia University Medical Center
2432
mi
from 91732
New York, NY
Click here to add this to my saved trials
An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
Status: Enrolling
Updated:  3/3/2014
1221
mi
from 91732
Dallas, TX
An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
Status: Enrolling
Updated: 3/3/2014
UT Southwestern Medical Center - Children's Medical Center Dallas
1221
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
Status: Enrolling
Updated:  3/3/2014
573
mi
from 91732
Salt Lake City, UT
An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
Status: Enrolling
Updated: 3/3/2014
University of Utah School of Medicine
573
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Neuromuscular Ultrasound in ALS
Ultrasonography in Amyotrophic Lateral Sclerosis as a Predictor of Disease Progression and Tool in Diagnosis: a Pilot Study
Status: Enrolling
Updated:  3/3/2014
2203
mi
from 91732
Durham, NC
Neuromuscular Ultrasound in ALS
Ultrasonography in Amyotrophic Lateral Sclerosis as a Predictor of Disease Progression and Tool in Diagnosis: a Pilot Study
Status: Enrolling
Updated: 3/3/2014
Duke Univ Med Ctr
2203
mi
from 91732
Durham, NC
Click here to add this to my saved trials
Extracellular Signal-Related Kinase Biomarker Development in Autism
Extracellular Signal-Related Kinase Biomarker Development in Autism
Status: Enrolling
Updated:  3/5/2014
1880
mi
from 91732
Cincinnati, OH
Extracellular Signal-Related Kinase Biomarker Development in Autism
Extracellular Signal-Related Kinase Biomarker Development in Autism
Status: Enrolling
Updated: 3/5/2014
Cincinnati Children's Hospital Medical Center
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Systemic Normothermia in Intracerebral Hemorrhage (ICH)
Systemic Normothermia in Intracerebral Hemorrhage (ICH)
Status: Enrolling
Updated:  3/5/2014
2035
mi
from 91732
Cleveland, OH
Systemic Normothermia in Intracerebral Hemorrhage (ICH)
Systemic Normothermia in Intracerebral Hemorrhage (ICH)
Status: Enrolling
Updated: 3/5/2014
Cleveland Clinic
2035
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
Status: Enrolling
Updated:  3/5/2014
1880
mi
from 91732
Cincinnati, OH
Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
Status: Enrolling
Updated: 3/5/2014
Cincinnati Children's Hospital Medical Center
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
21
mi
from 91732
Long Beach, CA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Collaborative Neuroscience Network, Inc.
21
mi
from 91732
Long Beach, CA
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
366
mi
from 91732
Sacramento, CA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
University of California, Davis Medical Center
366
mi
from 91732
Sacramento, CA
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
356
mi
from 91732
San Francisco, CA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
University of California at San Francisco (UCSF)
356
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
328
mi
from 91732
Stanford, CA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Stanford Univ Med Ctr
328
mi
from 91732
Stanford, CA
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
825
mi
from 91732
Aurora, CO
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
University of Colorado Denver
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
818
mi
from 91732
Centennial, CO
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
IMMUNOe
818
mi
from 91732
Centennial, CO
Click here to add this to my saved trials